CALGB 60301: SORAFENIB FOR SOLID TUMORS AND HAM MALIGNANCIES

CALGB 60301：索拉非尼治疗实体瘤和火腿恶性肿瘤

• 批准号: 7625606
• 负责人: ELIZABETH CLAIRE DEES
• 金额: $ 0.21万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7625606
• 关键词: BAY 43-9006; BAY 54-9085; Cancer and Leukemia Group B; Computer Retrieval of Information on Scientific Projects Database; Dose; Funding; Goals; Grant; Institution; Learning; Liver; Malignant Neoplasms; Patients; Pharmaceutical Preparations; Purpose; Renal function; Research; Research Personnel; Resources; Solid Neoplasm; Source; United States National Institutes of Health

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to learn what dose of BAY 43-9006 can be given safely to patients with abnormal liver or kidney function. Another goal of the study is to find out how the body handles the drug depending on liver and kidney function.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的目的是了解什么剂量的BAY 43-9006可以安全地给予肝功能或肾功能异常的患者。 这项研究的另一个目标是找出身体如何根据肝脏和肾脏功能处理药物。